NCT00529451View on ClinicalTrials.gov

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

PHASE3CompletedINTERVENTIONAL
Enrollment

1,613

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Hypertension
Interventions
DRUG

Aliskiren

Aliskiren

DRUG

Ramipril

comparator

Trial Locations (3)

Unknown

Novartis Investigative Sites, China

Novartis Investigative Sites, India

Novartis Investigative Sites, Thailand

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00529451 - Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg | Biotech Hunter | Biotech Hunter